Most teams think of trials as timelines, but they actually behave like dependency graphs with concurrent workstreams, conditional branches, and feedback loops. Site activation can't start until the IND clears and the IRB approves the protocol, but IRB review can overlap with contract negotiation, which depends on the clinical trial agreement. When any single dependency breaks, activation halts. CenterWatch surveys show over 90% of trials miss their original timeline, with site activation the leading cause. The typical Phase III study carries 2.3 unplanned amendments, and Tufts CSDD found that studies with at least one substantial amendment take three extra months to complete. That delay propagates through every downstream node: enrollment, monitoring, database lock. A 2018 cancer center survey reported median site activation time of 167 days against a 90-day NCI target, with 2024 data showing actual times ranging from 78 to 313 days. Roughly 10% of activated sites in global Phase III trials enroll zero patients, and 40% under-enroll relative to target. Mapping these dependencies makes it clear where intervention produces the most time savings.